These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 18171296

  • 21. Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.
    Bahr GM, Darcissac EC, Castéran N, Amiel C, Cocude C, Truong MJ, Dewulf J, Capron A, Mouton Y.
    J Virol; 2001 Aug; 75(15):6941-52. PubMed ID: 11435574
    [Abstract] [Full Text] [Related]

  • 22. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue.
    Goldstein H, Pettoello-Mantovani M, Anderson CM, Cordelier P, Pomerantz RJ, Strayer DS.
    J Infect Dis; 2002 May 15; 185(10):1425-30. PubMed ID: 11992277
    [Abstract] [Full Text] [Related]

  • 23. SCID-Hu mouse as a model for human lung HIV-1 infection.
    Cesbron JY, Agut H, Gosselin B, Candotti D, Raphaël M, Puech F, Grandadam M, Debré P, Capron A, Autran B.
    C R Acad Sci III; 1994 Jul 15; 317(7):669-74. PubMed ID: 7882151
    [Abstract] [Full Text] [Related]

  • 24. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
    Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H.
    J Virol; 2005 Feb 15; 79(4):2087-96. PubMed ID: 15681411
    [Abstract] [Full Text] [Related]

  • 25. T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells.
    Rizza P, Santini SM, Logozzi MA, Lapenta C, Sestili P, Gherardi G, Lande R, Spada M, Parlato S, Belardelli F, Fais S.
    J Virol; 1996 Nov 15; 70(11):7958-64. PubMed ID: 8892919
    [Abstract] [Full Text] [Related]

  • 26. Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels.
    Sailer CA, Pott GB, Dinarello CA, Whinney SM, Forster JE, Larson-Duran JK, Landay A, Al-Harthi L, Schooley RT, Benson CA, Judson FN, Thompson M, Palella FJ, Shapiro L.
    J Infect Dis; 2007 Mar 01; 195(5):734-8. PubMed ID: 17262717
    [Abstract] [Full Text] [Related]

  • 27. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice.
    Baenziger S, Tussiwand R, Schlaepfer E, Mazzucchelli L, Heikenwalder M, Kurrer MO, Behnke S, Frey J, Oxenius A, Joller H, Aguzzi A, Manz MG, Speck RF.
    Proc Natl Acad Sci U S A; 2006 Oct 24; 103(43):15951-6. PubMed ID: 17038503
    [Abstract] [Full Text] [Related]

  • 28. Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer.
    Khatri VP, Baiocchi RA, Bernstein ZP, Caligiuri MA.
    Cancer J Sci Am; 1997 Dec 24; 3 Suppl 1():S129-36. PubMed ID: 9457408
    [Abstract] [Full Text] [Related]

  • 29. Limitations of the human-PBL-SCID mouse model for vaginal transmission of HIV-1.
    D'Cruz OJ, Uckun FM.
    Am J Reprod Immunol; 2007 May 24; 57(5):353-60. PubMed ID: 17430499
    [Abstract] [Full Text] [Related]

  • 30. Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice.
    Garaci E, Aquaro S, Lapenta C, Amendola A, Spada M, Covaceuszach S, Perno CF, Belardelli F.
    Proc Natl Acad Sci U S A; 2003 Jul 22; 100(15):8927-32. PubMed ID: 12853577
    [Abstract] [Full Text] [Related]

  • 31. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy.
    Weiser B, Philpott S, Klimkait T, Burger H, Kitchen C, Bürgisser P, Gorgievski M, Perrin L, Piffaretti JC, Ledergerber B, Swiss HIV Cohort Study.
    AIDS; 2008 Feb 19; 22(4):469-79. PubMed ID: 18301059
    [Abstract] [Full Text] [Related]

  • 32. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.
    AIDS; 2008 Jul 31; 22(12):1425-31. PubMed ID: 18614865
    [Abstract] [Full Text] [Related]

  • 33. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.
    Stoddart CA, Bales CA, Bare JC, Chkhenkeli G, Galkina SA, Kinkade AN, Moreno ME, Rivera JM, Ronquillo RE, Sloan B, Black PL.
    PLoS One; 2007 Aug 01; 2(7):e655. PubMed ID: 17668043
    [Abstract] [Full Text] [Related]

  • 34. Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: possible involvement of a novel factor of human CD4(+) T-cell origin.
    Yoshida A, Tanaka R, Murakami T, Takahashi Y, Koyanagi Y, Nakamura M, Ito M, Yamamoto N, Tanaka Y.
    J Virol; 2003 Aug 01; 77(16):8719-28. PubMed ID: 12885891
    [Abstract] [Full Text] [Related]

  • 35. Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rgammanull mice.
    Nie C, Sato K, Misawa N, Kitayama H, Fujino H, Hiramatsu H, Heike T, Nakahata T, Tanaka Y, Ito M, Koyanagi Y.
    Virology; 2009 Nov 10; 394(1):64-72. PubMed ID: 19744686
    [Abstract] [Full Text] [Related]

  • 36. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model.
    Berges BK, Wheat WH, Palmer BE, Connick E, Akkina R.
    Retrovirology; 2006 Nov 01; 3():76. PubMed ID: 17078891
    [Abstract] [Full Text] [Related]

  • 37. The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS.
    Jamieson BD, Aldrovandi GM, Zack JA.
    Semin Immunol; 1996 Aug 01; 8(4):215-21. PubMed ID: 8883144
    [Abstract] [Full Text] [Related]

  • 38. HIV coreceptor phenotyping in the clinical setting.
    Low AJ, Swenson LC, Harrigan PR.
    AIDS Rev; 2008 Aug 01; 10(3):143-51. PubMed ID: 18820716
    [Abstract] [Full Text] [Related]

  • 39. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity.
    Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, Tanaka R, Hirose K, Bannai K, Edamatsu T, Yanaka M, Niitani Y, Miyano-Kurosaki N, Takaku H, Koyanagi Y, Yamamoto N.
    Proc Natl Acad Sci U S A; 2003 Apr 01; 100(7):4185-90. PubMed ID: 12642669
    [Abstract] [Full Text] [Related]

  • 40. Assessment of oral transmission using cell-free human immunodeficiency virus-1 in mice reconstituted with human peripheral blood leucocyte.
    Nakao R, Hanada N, Asano T, Hara T, Abdus Salam M, Matin K, Shimazu Y, Nakasone T, Horibata S, Aoba T, Honda M, Amagasa T, Senpuku H.
    Immunology; 2003 Jun 01; 109(2):271-82. PubMed ID: 12757623
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.